340b

Prohibitions on PBMs from discriminating against 340b pharmacies including network inclusion, reimbursement differences, or additional fees.

Filter by Document Type

2025 WI JFC Comment Letter

View Document >

2025 RI H 5634 Testimony

View Document >

2025 RI S 114 Testimony

View Document >

2025 NH SB 253 Testimony

View Document >

DE HB 383 Testimony: 340B (2024)

View Document >

MO SB 978, SB 1035 Comment Letter: 340B (2024)

View Document >

MO SB 751 Comment Letter: 340B, White Bagging (2024)

View Document >

340B Drug Pricing: Support Market Driven Transparency Efforts, Not Another Layer of Regulation (Talking Points, 2024)

View Document >

The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments (Karen Mulligan, PhD, USC Schaeffer Center)

View Document >

What is 340B Drug Pricing (One Pager, 2023)

One pager that explains what 340B pharmacies, and its reimbursement methods.

View Document >

MO SB 26 Comment Letter (2023)

Comment letter addressing white bagging, biosimiliars, and 340b provisions in MO SB 26.

View Document >

MO HB 442 Comment Letter (2023)

Comment Letter addressing 340b and copay accumulator provisions in MO HB 442.

View Document >